Primary Care Programs
Novel Treatment and Management Options for Chronic Idiopathic Constipation
Released on July 23, 2021
Expires on July 23, 2022
New Paradigms in the Treatment and Management of Neovascular Age-related Macular Degeneration (nAMD)
Released on June 29, 2021
Expires on June 29, 2022
New Paradigms for Treatment and Management of Retinal Vein Occlusion (RVO)
Released on June 14, 2021
Expires on June 14, 2022
New Paradigms in the Treatment and Management of Age-related Macular Degeneration (AMD)
Released on 4/30/21
Expires on 4/30/22
New Paradigms in the Biological Therapies for Atopic Dermatitis
Released on 3/10/20
Expires on 3/10/21
Emerging Strategies in the Management of Chronic Fibrosing ILD Patients Who Have Contracted COVID-19
Released on 10/28/20
Expires on 10/28/21
New Paradigms in the Prevention and Treatment of Migraine with HT1F Agonist and mAb Against CGRP Pathway or its Receptor
Released on 11/25/19
Expires on 11/25/20
New Horizons in Reducing Cardiovascular Disease Risk in Patients with Type 2 Diabetes with SGLT-2, GLP-1 RAs and DPP-4 Based Therapies
Released on 6/14/19
Expires on 6/14/20
Changing Landscape of GLP-1 Receptor Agonists on Glycemic Control, Weight Reduction and Cardiovascular Outcomes in Individuals with Diabetes
Released on 6/12/19
Expires on 6/12/20
Changing Landscape of Treatment Options for Migraine with Monoclonal Antibodies Targeting Calcitonin Gene-related Peptide (CGRP) Pathway or its Receptor
Released on 3/22/19
Expires on 3/22/20
Emerging Newer Therapies in the Management of Lung Function, Exacerbations, Safety and Tolerability in Patients with COPD
Released on 8/9/18
Expires on 8/9/19
Emerging Anti-Interleukin 5 (IL-5) and IL-5Ra Based Biological Therapies: Efficacy, Safety and Future Perspectives in Severe Eosinophilic Asthma
Released on 7/12/18
Expires on 7/12/19
Emerging Interleukin-5 (IL-5) or its Receptor (IL-5R) Monoclonal Antibody Based Biological Therapies for Severe or Poorly Controlled Asthma
Released on 6/29/18
Expires on 6/29/19
Emerging Strategies in the Diagnosis and Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD)
Released on 6/19/18
Expires on 6/19/19
New Era in the Lipid Lowering Treatment with PCSK9 Inhibitors (Evolocumab and Alirocumab) in Patients with Atherosclerotic Cardiovascular Disease and Familial Hypercholesterolemia
Released on 5/11/18
Expires on 5/11/19
Emerging Strategies in the Diagnosis and Treatment of Interstitial Lung Disease (ILD)
Released on 5/10/18
Expires on 5/10/19
Emerging Strategies in the Anti–Interleukin-5 Monoclonal Antibody Based Targeted Therapies for Eosinophilic Granulomatosis with Polyangiitis (EGPA)
Released on 2/6/18
Expires on 2/6/19
Efficacy and Safety of Fixed-ratio Combination of Insulin Degludec and Liraglutide (IDegLira) and Insulin Glargine and Lixisenatide (IGlarLixi) in Patients with Type 2 Diabetes
Released on 11/29/17
Expires on 11/29/18
Emerging Strategies in the Monoclonal Antibodies Targeting Calcitonin Gene-related Peptide (CGRP) or its Receptor in the Preventive Treatment of Migraine
Released on 11/17/17
Expires on 11/17/18
Emerging Strategies in the Management of Dyslipidemia in Patients with Atherosclerotic Cardiovascular Disease and Familial Hypercholesterolemia: PCSK9 Inhibitors (Evolocumab and Alirocumab)
Released on 10/10/17
Expires on 10/10/18
Changing Landscape of Biological Therapies for Psoriasis: Promising Efficacy of Interleukin-17 (IL-17) and IL-2 Pathway Inhibitors
Released on 9/20/17
Expires on 9/20/18
Advances in Biological Therapy of Crohn's Disease and Ulcerative Colitis
Released on 8/10/17
Expires on 8/10/18
Emerging Immunotherapeutic Strategies for Poorly Controlled Asthma
Released on 7/20/17
Expires on 7/20/18
Advances in GLP-1 Receptor Agonists, Insulins and SGLT-2 Inhibitors in the Treatment of Diabetes
Released on 5/12/17
Expires on 5/12/18
Individualized Treatment Options for Type 2 Diabetes: Comparative Effectiveness of GLP-1 Receptor Agonists on Glycemic Control, Weight Reduction and Cardiovascular Risk
Released on 4/20/17
Expires on 4/20/18
Emerging Strategies in the Treatment of Parkinson's Disease: Management of Non-Motor, Motor and Psychotic Symptoms
Released on 2/24/17
Expires on 2/24/18
Emerging Biological Therapies for Atopic Dermatitis in Children and Adults
Released on 2/15/17
Expires on 2/15/18
Biological Therapies for PsA, Osteoarthritis, SLE and Spondyloarthritis: Comparative Effectiveness Based on Treatment Profiles and ACR/EULAR Recommendations
Released on 12/15/16
Expires on 12/15/17
Emerging Interleukin5 (IL5) Antagonists Based Therapies for Eosinophilic Asthma
Released on 10/31/16
Expires on 10/31/17
Emerging Biological Therapies for Psoriasis: Promising Efficacy of Interleukin‐17 (IL‐17) and IL‐23 Pathway Inhibitors
Released on 10/28/16
Expires on 10/28/17
3rd Annual Symposium on Individualized Novel Disease-Modifying Treatment Options for Multiple Sclerosis
Released on 10/26/2016
Expires on 10/26/2017
Update on Novel Antiepileptic Drugs in Treatment of Epilepsy
Released on 9/28/16
Expires on 9/28/17
Emerging Immunotherapeutic Strategies for Poorly Controlled Asthma
Released on 7/20/2016
Expires on 7/20/2017
Update on GLP-1 Receptor Agonists in the Management of Type 2 Diabetes Mellitus
Released on 7/7/16
Expires on 7/7/17
Oncology/Hematology Programs
Changing Landscape of Treatment for Acute Lymphoblastic Leukemia
Released on May 26, 2021
Expires on May 26, 2022
Biosimilars: Implications for Clinical Practice in Hematological Malignancies & Supportive Care
Released on 4/30/21
Expires on 4/30/22
Update on the Immune Checkpoint Inhibitor and Combination Targeted Therapies for Hepatocellular Carcinoma
Released on 3/18/20
Expires on 3/18/21
Changing Landscape of NSCLC with Targeted Therapies and Immunotherapy
Released on 12/08/20
Expires on 12/08/21
Advances in the Treatment of dMMR/MSI-H Colorectal Cancer with Immunotherapy
Released on 12/05/20
Expires on 12/05/21
Changing Landscape of Treatment Options for Multiple Myeloma
Released on 10/5/20
Expires on 10/5/21
Changing Landscape of Treatment Options for Hematological Malignancies
Released on 9/28/20
Expires on 9/28/21
Current and Emerging Treatment Options for Renal Cell Carcinoma
Released on 10/10/20
Expires on 10/18/21
Current and Emerging Treatment Options for Lung Cancer and Head & Neck Cancer
Released on 7/22/21
Expires on 7/30/21
Current and Emerging Treatment Options for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Carcinoma)
Released on 6/15/20
Expires on 6/15/21
Changing Landscape of Treatment Options for Metastatic Urothelial Carcinoma
Released on 5/22/20
Expires on 5/22/21
New Paradigms in the Treatment of Relapsed Multiple Myeloma
Released on 5/3/20
Expires on 5/3/21
New Paradigms in the Treatment Options for Acute Lymphoblastic Leukemia (ALL) and Acute Myeloid Leukemia (AML): European Perspective
Released on 4/28/20
Expires on 4/28/21
Current and Emerging Treatment Options for Lung Cancer and Head & Neck Carcinoma
Released on 12/30/19
Expires on 12/30/20
Changing Landscape of Treatment of HR+ and HER2- Metastatic Breast Cancer with PI3K and CDK 4/6 Inhibitors
Released on 12/26/19
Expires on 12/26/20
Changing Landscape of Treatment Options for ALL with CD19, CD22 Monoclonal Antibodies and AML with IDH1/2, FLT3, CD33 and Hedgehog Pathway Targeted Agents
Released on 9/17/19
Expires on 9/17/20
Evolving Landscape of Treatment for Hepatocellular Carcinoma with Multi-Targeted Tyrosine Kinase Inhibitors and Immunotherapy
Released on 6/24/19
Expires on 6/24/20
Changing Landscape of Targeted and Immunotherapies for Genitourinary Cancers
Released on 6/12/19
Expires on 6/12/20
Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma with Anti-PD-1/PD-L1 Agents
Released on 6/10/19
Expires on 6/10/20
New Paradigms in the Treatment of Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia
Released on 5/13/19
Expires on 5/13/20
Optimizing Outcomes in Patients with Malignant Melanoma Treated with Targeted Agents, Checkpoint Inhibitors and Oncolytic Viral Therapies
Released on 12/30/18
Expires on 12/30/19
Emerging Novel PI3K Inhibitors, Anti-CD20 mAb and Combination Therapy Options for Follicular Lymphoma
Released on 12/30/18
Expires on 12/30/19
Changing Landscape of Treatment Strategies of TKI Interruptions, Discontinuations and Switching in Patients with Chronic Myeloid Leukemia
Released on 12/30/18
Expires on 12/30/19
Update on Treatment Options for Acute Lymphoblastic Leukemia with An Emphasis on CD19, CD22 Monoclonal Antibodies and Anti-CD19 CAR T-cell Therapy
Released on 12/30/18
Expires on 12/30/19
Changing Treatment Paradigms with Immunotherapy and Targeted Therapy in Advanced Non-Small-Cell Lung Cancer and Head & Neck Cancer
Released on 11/7/18
Expires on 11/7/19
Emerging Treatment Options for Genomic Subgroups of Acute Myeloid Leukemia with IDH1/2, FLT3 and CD33 Targeted Agents
Released on 10/19/18
Expires on 10/19/19
Emerging Strategies in Novel Targeted Therapies for Genitourinary Cancers (Prostate Cancer, Renal Cell Carcinoma and Urothelial Bladder Carcinoma)
Released on 9/28/18
Expires on 9/28/19
Emerging Novel Anti-CD20 mAb, PI3K Inhibitors and Combination Therapy Options for Follicular Lymphoma
Released on 8/15/18
Expires on 8/15/19
Mapping the Future Treatment Options with Multitargeted TKIs and Checkpoint Inhibitors for Metastatic Renal Cell Carcinoma
Released on 8/15/18
Expires on 8/15/19
Mapping the Current and Future Treatment Options for Advanced Soft Tissue Sarcoma Including Liposarcoma and Leiomyosarcoma
Released on 8/15/18
Expires on 8/15/19
7th Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia
Released on 7/2/18
Expires on 7/2/19
Immunotherapy with Anti-PD-1/PD-L1 Agents Are New Effective Therapies for Recurring and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
Released on 6/29/18
Expires on- 6/29/19
Advances in the Treatment of Acute Lymphoblastic Leukemia with An Emphasis on CD22 and CD19 Monoclonal Antibodies
Released on 4/25/18
Expires on 4/25/19
Emerging Strategies in the Diagnosis, Treatment and the Concept of Treatment-free Remission in Chronic Myeloid Leukemia
Released on 12/28/17
Expires on 12/28/18
Changing Landscape of Novel Combination Therapies for Patients with Newly Diagnosed, Risk Stratified and Relapsed/Refractory Multiple Myeloma
Released on 12/20/17
Expires on 12/20/18
Emerging Checkpoint Inhibitor and Combination Based Therapies for Relapsed or Refractory Hodgkin's Lymphoma
Released on 12/20/17
Expires on 12/20/18
Update on Treatment Options for Leukemia: Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Acute Myeloid Leukemia and Chronic Myeloid Leukemia
Released on 11/30/17
Expires on 11/30/18
Novel Therapeutic Approaches of EGFR-, ALK-rearranged Targeted Therapies and Immunotherapy of Lung Cancer
Released on 10/6/17
Expires on 10/6/18
Emerging Strategies in Targeted Therapy of Advanced Gastric or Gastro-esophageal Junction Adenocarcinoma
Released on 9/13/17
Expires on 9/13/18
Emerging Treatment Option with CDK 4/6 Inhibitors for Hormone Receptor-positive Breast Cancer: Insight into Clinical Activity and Safety Profile
Released on 8/8/17
Expires on 8/8/18
6th Annual Symposium on Current Strategies in the Treatment of Hodgkins Lymphoma, B-cell Lymphoma, Multiple Myeloma and Leukemia
Released on 7/28/17
Expires on 7/28/18
Emerging Strategies in the Treatment of Metastatic Urothelial Bladder Carcinoma: Outlook for 2017
Released on 7/26/17
Expires on 7/26/18
Emerging Treatment Options for Metastatic Renal Cell Carcinoma
Released on 5/11/17
Expires on 5/11/18
Changing Paradigms in the Diagnosis and Treatment of Multiple Myeloma
Released on 3/10/2017
Expired on 3/10/2018
Update on Immunotherapy Options for Non-Small Cell Lung Cancer
Released on 3/6/17
Expires on 3/6/18
Practice Changing Shift in Treatment Strategies for Advanced Soft Tissue Sarcoma, Liposarcoma and Leiomyosarcoma
Released on 2/16/17
Expires on 2/16/18
Practice Changing Treatment with CDK 4/6 Inhibitors for Hormone Receptor‐Positive Breast Cancer
Released on 12/30/16
Expires on 12/30/17
Emerging Strategies in Treatment of Hodgkin Lymphoma and Non‐Hodgkin Lymphoma
Released on 12/29/16
Expires on 12/29/17
Emerging Immunotherapy Options for Relapsed or Refractory Hodgkin's Lymphoma
Released on 12/20/16
Expires on 12/20/17
Novel Therapeutic Approaches for Patients with Squamous Cell Carcinoma of the Head and Neck
Released on 11/15/16
Expires on 11/15/17
Novel Treatment Approaches for Non-Small-Cell Lung Cancer: A 2016 Update
Released on 10/25/16
Expires on 10/25/17
Novel Therapeutic Options for Acute Lymphoblastic Leukemia
Released on 7/21/16
Expires on 7/21/17
Advances in the Treatment Options for Liposarcoma/Leiomyosarcoma and Soft Tissue Sarcoma
Released on 7/21/16
Expires on 7/21/17
Novel Therapies for Malignant Melanoma: Immune Checkpoint Inhibitors, Targeted BRAF Inhibitors and Oncolytic Viral Therapy Approaches
Released on 7/7/16
Expires on 7/7/17
Emerging Strategies in the Treatment of Chronic Lymphocytic Lymphoma
Released on 7/1/16
Expires on 7/7/17
Personalized, Genotype-directed Therapy for Advanced Non-Small Cell Lung Cancer
Released on 6/30/2016
Expires on 6/30/2017
Changing Landscape in the Treatment of Metastatic Renal Cell Carcinoma and Bladder Cancer: Newer Insights
Released on 6/30/2016
Expires on 6/30/2017
Molecular Prognostic and Predictive Biomarkers Based Targeted Treatment of Colorectal Cancer
Released on 6/30/2016
Expires on 6/30/2017
5th Annual Symposium on Current Strategies in the Management of B-cell Lymphomas, T-cell Lymphomas, Multiple Myeloma and Leukemia
Released on 6/27/2016
Expires on 6/27/2016